CT26-hCD24/hPDL1
Strain Information
Validation Data
Ⅰ.In vitro Expression of CT26-hCD24/hPDL1 cell line
Figure 1. hCD24 and hPDL1 expression in CT26-hCD24/hPDL1 cell line
Ⅱ.Characterization of in vivo growth kinetics
To test the take rates, and the tumor growth characteristics of CT26-hCD24/hPDL1 cell line, cells were subcutaneously inoculated into the Balb/c mice.
Figure 2. Tumor growth curve of CT26-hCD24/hPDL1 syngeneic model
Figure 3. Body weight change of CT26-hCD24/hPDL1 syngeneic model
Ⅲ.Expression of hCD24 and hPDL1 protein in tumors
Figure 4. The expression of hCD24 and hPDL1 in humanized modified tumors by FACS
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
